Journal of Genetic Medicine : eISSN 2383-8442 / pISSN 1226-1769

Fig. 1.

Download original image
Fig. 1. Current approaches for targeting pathways in NF1-associated tumorigenesis. Inhibitors of RAF, MEK, and ERK specifically target the MAPK pathway. In contrast, mTOR inhibitors focus on the PI3K/AKT/mTOR pathway. Both receptor tyrosine kinase (RTK) inhibitors and SHP2 inhibitors influence both pathways.
Journal of Genetic Medicine 2024;21:51-60 https://doi.org/10.5734/JGM.2024.21.2.51
© 2024 Korean Society of Medical Genetics and Genomics